A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia

被引：2

作者：

Qian, Jiejing ^{[1
]}

Xu, Jieyu ^{[1
,2
]}

Hong, Qing ^{[1
,2
]}

Lou, Yinjun ^{[1
]}

Mao, Liping ^{[1
]}

Xu, Weilai ^{[1
]}

Yang, Min ^{[3
]}

Yu, Wenjuan ^{[1
,4
]}

Meng, Haitao ^{[1
]}

Mai, Wenyuan

Ye, Xiujing ^{[5
]}

Zhu, Honghu ^{[1
]}

Jin, Jie ^{[1
,6
,7
,8
,9
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China

[2] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China

[3] Zhejiang Univ Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China

[5] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China

[6] Key Lab Hematol Malignancies Diag & Treatment, Hangzhou, Peoples R China

[7] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China

[8] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China

[9] Clin Res Ctr Hematol Disorders, Hangzhou, Zhejiang, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-149523

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4414

引用

页数：3

共 50 条

[31] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
Short, Nicholas J.
Sedarati, Farhad
Zhao, Dan
Tsukurov, Olga
Friedlander, Sharon
Faller, Douglas V.
BLOOD, 2020, 136
[32] Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
DiNardo, Courtney D.
Lachowiez, Curtis A.
Takahashi, Koichi
Loghavi, Sanam
Kadia, Tapan
Daver, Naval
Xiao, Lianchun
Adeoti, Maria
Short, Nicholas J.
Sasaki, Koji
Wang, Sa A.
Borthakur, Gautam
Issa, Ghayas
Maiti, Abhishek
Alvarado, Yesid
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Masarova, Lucia
Yilmaz, Musa
Jain, Nitin
Andreeff, Michael
Garcia-Manero, Guillermo
Kornblau, Steven
Ravandi, Farhad
Jabbour, Elias
Konopleva, Marina Y.
Kantarjian, Hagop M.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : 1035 - 1043
[33] Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia
Lachowiez, Curtis
DiNardo, Courtney D.
Takahashi, Koichi
Loghavi, Sanam
Xiao, Lian-Chun
Kadia, Tapan M.
Daver, Naval
Adeoti, Maria
Short, Nicholas J.
Sasaki, Koji
Wang, Sa A.
Borthakur, Gautam
Issa, Ghayas C.
Maiti, Abhishek
Alvarado, Yesid
Pemmaraju, Naveen
Montalban-Bravo, Guillermo
Masarova, Lucia
Masarova, Lucia
Jain, Nitin
Andreeff, Michael
Garcia-Manero, Guillermo
Kornblau, Steven M.
Ravandi, Farhad
Jabbour, Elias J.
Konopleva, Marina
Kantarjian, Hagop
BLOOD, 2021, 138
[34] Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia
Lachowiez, Curtis
Takahashi, Koichi
Loghavi, Sanam
Xiao, Lianchun
Kadia, Tapan
Adeoti, Maria
Short, Nicholas
Sasaki, Koji
Wang, Sa
Borthakur, Gautam
Issa, Ghayas
Maiti, Abhishek
Alvarado, Yesid
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Masarova, Lucia
Yilmaz, Musa
Jain, Nitin
Andreeff, Michael
Jabbour, Elias
Garcia-Manero, Guillermo
Kornblau, Steven
Ravandi, Farhad
Konopleva, Marina
Kantarjian, Hagop
DiNardo, Courtney
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S291 - S291
[35] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Maximilian Fleischmann
Sebastian Scholl
Jochen J. Frietsch
Inken Hilgendorf
Karin Schrenk
Jakob Hammersen
Florian Prims
Christian Thiede
Andreas Hochhaus
Ulf Schnetzke
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
[36] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
Jonas, Brian A.
Wei, Andrew H.
Recher, Christian
DiNardo, Courtney D.
Jang, Jun-Ho
Pratz, Keith
Panayiotidis, Panayiotis
Montesinos, Pau
Yeh, Su-Peng
Ivanov, Vladimir
Fiedler, Walter
Yamauchi, Takahiro
Duan, Yinghui
Mendes, Wellington
Potluri, Jalaja
Tews, Bjorn
Ofran, Yishai
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
[37] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Fleischmann, Maximilian
Scholl, Sebastian
Frietsch, Jochen J.
Hilgendorf, Inken
Schrenk, Karin
Hammersen, Jakob
Prims, Florian
Thiede, Christian
Hochhaus, Andreas
Schnetzke, Ulf
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
[38] Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
Cui, Jingying
Chen, Xuexing
Li, Chunfang
Yan, Qiong
Yuan, Guolin
HEMATOLOGY, 2024, 29 (01)
[39] DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS
Zannoni, L.
Forte, D.
Sartor, C.
Cristiano, G.
Nanni, J.
Parisi, S.
Zingarelli, F.
Bandini, L.
Testoni, N.
Ottaviani, E.
Paolini, S.
Papayannidis, C.
Cavo, M.
Rutella, S.
Curti, A.
HAEMATOLOGICA, 2024, 109 : 74 - 75
[40] A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study
Smith, B. Douglas
Lachowiez, Curtis A.
Ambinder, Alexander Joseph
Binder, Gary
Angiolillo, Anne
Vestin, Assaf
Paglia, Robert
Potluri, Ravi
Papademetriou, Eros
LeBlanc, Thomas W.
BLOOD, 2023, 142

← 1 2 3 4 5 →